Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of Medicine has hosted or co-hosted six domestic and international workshops addressing the global crisis of drug-resistant TB, with special attention to the BRICS countries - Brazil, Russia, India, China, and South Africa.
The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS is the summary of a workshop convened to address the current status of drug-resistant TB globally and in China. This report considers lessons learned from high burden countries; highlights global challenges to controlling the spread of drug-resistant strains; and discusses innovative strategies to advance and harmonize local and international efforts to prevent and treat drug-resistant TB. Additionally, the report examines the problem of MDR TB and emergent TB strains that are potentially untreatable with drugs available and considers the critical leadership role of the BRICS countries in addressing the threats and opportunities in drug-resistant TB.
Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. https://doi.org/10.17226/18346.
|1 Introduction and Overview of the Workshop||1-10|
|2 The Challenges and Opportunities for the BRICS Countries to Lead||11-22|
|3 Catching Up with the Microbe||23-30|
|4 Drug-Resistant TB in China||31-44|
|5 Experiences with MDR TB in Other Countries||45-54|
|6 Drug-Resistant Tuberculosis in Pediatric Populations||55-62|
|7 Global Perspectives on Transmission and Infection Control||63-78|
|8 Rapid Diagnostic Technologies: Status and Limitations||79-90|
|9 Addressing Diagnosis and Treatment Across the Spectrum of Drug Resistance||91-108|
|10 Developing and Strengthening the Drug Supply Chain for Drug-Resistant TB||109-118|
|11 Embracing a New Vision for Research||119-128|
|12 What Will Be Required to Achieve Zero Deaths from TB?||129-136|
|13 Creating an Evidence-Based Blueprint for Action||137-142|
|Appendix A: Workshop Agenda||151-170|
|Appendix B: Participant Biographies||171-196|
The Chapter Skim search tool presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter. You may select key terms to highlight them within pages of each chapter.
The National Academies Press (NAP) has partnered with Copyright Clearance Center's Rightslink service to offer you a variety of options for reusing NAP content. Through Rightslink, you may request permission to reprint NAP content in another publication, course pack, secure website, or other media. Rightslink allows you to instantly obtain permission, pay related fees, and print a license directly from the NAP website. The complete terms and conditions of your reuse license can be found in the license agreement that will be made available to you during the online order process. To request permission through Rightslink you are required to create an account by filling out a simple online form. The following list describes license reuses offered by the National Academies Press (NAP) through Rightslink:
Click here to obtain permission for the above reuses.If you have questions or comments concerning the Rightslink service, please contact:
Rightslink Customer Care
Tel (toll free): 877/622-5543
To request permission to distribute a PDF, please contact our Customer Service Department at 800-624-6242 for pricing.
To request permission to translate a book published by the National Academies Press or its imprint, the Joseph Henry Press, pleaseclick here to view more information.